EVAluation of Erythrocytosis PRospEctive Cohort STudy

Launched by CYRUS HSIA · Jan 19, 2025

Keywords

ClinConnect Summary

The EVEREST clinical trial is a study focused on understanding erythrocytosis, a condition where there is an abnormally high level of red blood cells in the body. This research aims to improve how doctors diagnose and manage patients with elevated hemoglobin levels, which can be linked to various health issues. By gathering detailed information over time, the study hopes to provide insights that will help patients receive better care.

To participate in this trial, individuals must be adults aged 18 or older who have been referred to hematology clinics and have specific hemoglobin levels (at least 165 g/L for men and 160 g/L for women). Participants should be able to understand and agree to take part in the study. If you meet these criteria, you could contribute to important findings in this area. The trial is not yet recruiting participants, but when it begins, those who join will help shape future approaches to treating conditions related to high red blood cell counts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients (\>=18 years) referred to hematology clinics at London Health Sciences Centre with hemoglobin levels \>=165 g/L in males or \>=160 g/L in females.
• • 2. Patients capable of providing informed consent.
• • 3. Age \>= 18 years.
• Exclusion Criteria:
• • 1. Patients \<18 years.
• • 2. Patients without erythrocytosis.
• • 3. Patients incapable of providing informed consent.